Early Virological Response of the First Line Combination Therapy (Pegylated Interferon I-2a and Ribavirin) in Iraqi Chronic Hepatitis C Patients and Their Psychological Adverse Effects
This study was designed to assess short-term therapeutic effectiveness and psychological adverse effects of combination of pegylated interferon α-2a and ribavirin in Iraqi chronic hepatitis C patients. For this purpose fifty newly diagnosed chronic hepatitis C patients divided into three groups A, B and C, treated with equal doses of pegylated interferon α-2a (180 μg/week) and different doses of ribavirin (1200, 1000 and 800 mg/day respectively) and followed up for 12 weeks of starting treatment (prospective groups). Twenty healthy subjects were selected to be a normal group for the purpose of comparison. The results at week 12 (the time of achieving EVR) showed 100% complete EVR (cEVR) in group A, 94.4% cEVR and 5.6% null response in group B, 88.9% cEVR and 11.1% partial response in group C. The prevalence of major depression 3 months after starting treatment, in group A was 28.6%, while in groups B and C were the same (27.8%). In conclusion, combination therapy with Pegylated interferon α-2a and ribavirin is highly effective in early eradication of hepatitis C virus in Iraqi chronic hepatitis C patients and can be used relatively safely, and development of major depressive symptoms occurred frequently.
